Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Real-World Comparative Effectiveness of First-Line Ipilimumab and Nivolumab vs Axitinib and Pembrolizumab in mRCC
  2. Molecular Characterization of Tumors in Sunitinib-Treated Patients With RCC at a High Risk of Recurrence After Nephrectomy
  3. Prognostic Value of Baseline and Early Variations of Peripheral Blood Inflammatory Ratios and Their Cellular Components in mRCC Treated With Nivolumab
  4. Body Composition Characteristics Affecting Clinical Outcomes of Patients With Metastatic ccRCC Treated With Immune Checkpoint Blockade
  5. Effect of Expanding Therapeutic Options on the Survival Trends Among Older Patients With mRCC
  6. Sapanisertib With or Without TAK-117 vs Everolimus in Patients With Advanced in Patients With Advanced RCC After VEGF-Targeted Therapy
  7. Validity of a Nomogram Developed to Predict Intraoperative Adverse Events During Robot-Assisted Partial Nephrectomy
  8. Association of Cachexia Index Score With Survival Outcomes in Patients With mRCC Treated With Immunotherapy
  9. Cost-Effectiveness of Adjuvant Pembrolizumab After Nephrectomy for High-Risk Clear Cell Renal Cell Carcinoma
  10. Association of CRP Levels With Efficacy of Avelumab Plus Axitinib in Patients With Advanced RCC

Elsewhere

Recently Updated